Ines Garcia-Consuegra1,2,3, Alberto Blázquez1,2,3, Juan Carlos Rubio1,2,3, Joaquín Arenas1,2,3, Alfonsina Ballester-Lopez4, Adrián González-Quintana1,2, Antoni L Andreu5, Tomàs Pinós3,6, Jaume Coll-Cantí4,7, Alejandro Lucia2,8, Gisela Nogales-Gadea4, Miguel A Martín1,2,3. 1. Laboratorio de Enfermedades Mitocondriales y Neuromusculares, Hospital 12 de Octubre, Madrid, Spain. 2. Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain. 3. Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain. 4. Translational Research Laboratory in Neuromuscular Diseases, Department of Neurosciences, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol i Campus Can Ruti, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain. 5. Hospital Universitari de Bellvitge, Hospitalet del Llobregat, Barcelona, Spain. 6. Institut de Recerca Val d'Hebron, Barcelona, Spain. 7. Unidad Neuromuscular, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. 8. Universidad Europea, Madrid, Spain.
Abstract
PURPOSE: McArdle disease is a metabolic disorder caused by pathogenic mutations in the PYGM gene. Timely diagnosis can sometimes be difficult with direct genomic analysis, which requires additional studies of cDNA from muscle transcripts. Although the "nonsense-mediated mRNA decay" (NMD) eliminates tissue-specific aberrant transcripts, there is some residual transcription of tissue-specific genes in virtually all cells, such as peripheral blood mononuclear cells (PBMCs). METHODS: We studied a subset of the main types of PYGM mutations (deletions, missense, nonsense, silent, or splicing mutations) in cDNA from easily accessible cells (PBMCs) in 12 McArdle patients. RESULTS: Analysis of cDNA from PBMCs allowed detection of all mutations. Importantly, the effects of mutations with unknown pathogenicity (silent and splicing mutations) were characterized in PBMCs. Because the NMD mechanism does not seem to operate in nonspecific cells, PBMCs were more suitable than muscle biopsies for detecting the pathogenicity of some PYGM mutations, notably the silent mutation c.645G>A (p.K215=), whose effect in the splicing of intron 6 was unnoticed in previous muscle transcriptomic studies. CONCLUSION: We propose considering the use of PBMCs for detecting mutations that are thought to cause McArdle disease, particularly for studying their actual pathogenicity.Genet Med 18 11, 1128-1135.
PURPOSE: McArdle disease is a metabolic disorder caused by pathogenic mutations in the PYGM gene. Timely diagnosis can sometimes be difficult with direct genomic analysis, which requires additional studies of cDNA from muscle transcripts. Although the "nonsense-mediated mRNA decay" (NMD) eliminates tissue-specific aberrant transcripts, there is some residual transcription of tissue-specific genes in virtually all cells, such as peripheral blood mononuclear cells (PBMCs). METHODS: We studied a subset of the main types of PYGM mutations (deletions, missense, nonsense, silent, or splicing mutations) in cDNA from easily accessible cells (PBMCs) in 12 McArdle patients. RESULTS: Analysis of cDNA from PBMCs allowed detection of all mutations. Importantly, the effects of mutations with unknown pathogenicity (silent and splicing mutations) were characterized in PBMCs. Because the NMD mechanism does not seem to operate in nonspecific cells, PBMCs were more suitable than muscle biopsies for detecting the pathogenicity of some PYGM mutations, notably the silent mutation c.645G>A (p.K215=), whose effect in the splicing of intron 6 was unnoticed in previous muscle transcriptomic studies. CONCLUSION: We propose considering the use of PBMCs for detecting mutations that are thought to cause McArdle disease, particularly for studying their actual pathogenicity.Genet Med 18 11, 1128-1135.
Authors: Alejandro Lucia; Jonatan R Ruiz; Alfredo Santalla; Gisela Nogales-Gadea; Juan C Rubio; Inés García-Consuegra; Ana Cabello; Margarita Pérez; Susana Teijeira; Irene Vieitez; Carmen Navarro; Joaquín Arenas; Miguel A Martin; Antoni L Andreu Journal: J Neurol Neurosurg Psychiatry Date: 2012-01-16 Impact factor: 10.154
Authors: N De Luna; A Freixas; P Gallano; L Caselles; R Rojas-García; C Paradas; G Nogales; R Dominguez-Perles; L Gonzalez-Quereda; J J Vílchez; C Márquez; J Bautista; A Guerrero; J A Salazar; A Pou; I Illa; E Gallardo Journal: Neuromuscul Disord Date: 2006-10-27 Impact factor: 4.296
Authors: M Meznaric; L Gonzalez-Quereda; E Gallardo; N de Luna; P Gallano; M Fanin; C Angelini; B Peterlin; J Zidar Journal: Eur J Neurol Date: 2010-10-18 Impact factor: 6.089
Authors: Gisela Nogales-Gadea; Tomàs Pinós; Antoni L Andreu; Miguel A Martín; Joaquin Arenas; Alejandro Lucia Journal: Genet Med Date: 2015-08 Impact factor: 8.822
Authors: Eduard Gallardo; Noemi de Luna; Jordi Diaz-Manera; Ricardo Rojas-García; Lidia Gonzalez-Quereda; Bàrbara Flix; Antoine de Morrée; Silvère van der Maarel; Isabel Illa Journal: PLoS One Date: 2011-12-16 Impact factor: 3.240
Authors: Inés García-Consuegra; Sara Asensio-Peña; Rocío Garrido-Moraga; Tomàs Pinós; Cristina Domínguez-González; Alfredo Santalla; Gisela Nogales-Gadea; Pablo Serrano-Lorenzo; Antoni L Andreu; Joaquín Arenas; José L Zugaza; Alejandro Lucia; Miguel A Martín Journal: Int J Mol Sci Date: 2022-04-22 Impact factor: 6.208
Authors: Mónica Villarreal-Salazar; Astrid Brull; Gisela Nogales-Gadea; Antoni L Andreu; Miguel A Martín; Joaquín Arenas; Alfredo Santalla; Alejandro Lucia; John Vissing; Thomas O Krag; Tomàs Pinós Journal: Genes (Basel) Date: 2021-12-28 Impact factor: 4.096